A Discourse Across Borders and
the Importance of Universal Design
Founder & CEO, SOLUtion Medical
Adrenal Crisis: A Discourse Across Borders and the Importance of Universal Design
Julia Anthony leads a discussion with Dr. Mitchell Geffner and individuals and families living with adrenal disease from around the globe.
The discussion will be joined by:
- Mitchell Geffner, MD
- Jenna Whaley Coura
- Ify Aforka
- Berryl Sawyers Hook
- Shaffali Deepak Khanna
- Rachel Pegler Doodledays
- Sam Iliades
Julia is the Founder & CEO of SOLUtion Medical — a life science company developing more patient friendly drug delivery systems for reconstitutable drugs. Together with its affiliates, SOLUtion has and continues to advance social medical device innovation especially within the adrenal insufficiency sphere.
A graduate of West Chester University where she studied Kinesiology and Nutrition, Julia earned her M.S. in Industrial Design from Jefferson University, concentrating in medical device creation and user interaction. A scholar athlete who diligently practices self-improvement, Julia thoroughly enjoys learning. Julia actively advocates and educates on behalf of the rare disease community and serves on the Young Adult Advisory Board for the CARES Foundation. As a young woman living with a rare medical condition, Julia brings her experience and rigor as a designer, entrepreneur, healthcare professional and patient to the life sciences.
SOLUtion Medical is developing a drug delivery device for patient-injected medications that require mixing directly prior to injection. The self-injection market is growing. Worldwide healthcare is trending towards more at-home treatments and pharma companies are seeking ways to deliver high-volume drugs for self-treatment in a timely manner. The self-injected drug delivery market is approximately $38B and has been growing at a CAGR of 19%. A large percentage of these drugs currently require lyophilization, and the FDA predicts 50% of all injectable drugs will require reconstitution in the near future.
SOLUtion’s beachhead market is a rescue autoinjector for individuals at risk of an adrenal crisis, a situation similar to anaphylaxis where a patient’s body experiences physical and mental debilitation requiring immediate injection of hydrocortisone sodium succinate (HSS). The current and only adrenal crisis rescue injection on the market comes in the form of the Act-o-Vial, a system requiring 14 user steps, including cumbersome drug mixing, prior to injection.
SOLUtion Medical is solving this problem with our patent-pending combination drug delivery device which requires only one step to mix the needed life-saving medication and prepare the device for injection. Our device automatically removes air and can be activated in any orientation. With our simpler, faster, and safer solution we aim to improve user experience, increase adherence, improve outcomes, decrease healthcare burden, and, most importantly, save lives.
In addition to the $320m adrenal crisis rescue injection market, numerous drugs currently exist that must be mixed directly prior to injection, including many antipshychotic drugs, in vitro fertilization drugs, monoclonal antibodies, cancer treatments, and multiple in-pipeline drugs. These are all multibillion dollar markets with specific and defined spaces where a device such as SOLUtion’s can gain traction and provide significant benefits to patients.